Human Enterovirus 71 Protein Displayed on the Surface of Saccharomyces cerevisiae as an Oral Vaccine

• Published in: Viral immunology Vol. 29; no. 5; pp. 288 - 295
• Main Authors: Zhang, Congdang, Wang, Yi, Ma, Shuzhi, Li, Leike, Chen, Liyun, Yan, Huimin, Peng, Tao
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc 01.06.2016
• Subjects: Administration, Oral; Animals; Animals, Newborn; Antibodies, Neutralizing - biosynthesis; Antibodies, Viral - biosynthesis; Capsid Proteins - genetics; Capsid Proteins - immunology; Enterovirus A, Human - growth & development; Enterovirus A, Human - immunology; Enterovirus Infections - immunology; Enterovirus Infections - prevention & control; Enterovirus Infections - virology; Female; Human enterovirus 71; Humans; Immunity, Humoral; Immunity, Maternally-Acquired; Immunity, Mucosal; Immunization Schedule; Immunogenicity, Vaccine; Membrane Proteins - genetics; Membrane Proteins - immunology; Mice; Mice, Inbred BALB C; Original Research Articles; Saccharomyces cerevisiae; Saccharomyces cerevisiae - genetics; Saccharomyces cerevisiae - immunology; Th1 Cells - immunology; Th1 Cells - virology; Transgenes; Vaccination; Viral Vaccines - administration & dosage; Viral Vaccines - genetics; Viral Vaccines - immunology
• ISSN: 0882-8245; 1557-8976
• DOI: 10.1089/vim.2015.0110

Human enterovirus 71 (EV-A71), a major agent of hand, foot, and mouth disease, has become an important public health issue in recent years. No effective antiviral or vaccines against EV-A71 infection are currently available. EV-A71 infection intrudes bodies through the gastric mucosal surface and it is necessary to enhance mucosal immune response to protect children from these pathogens. Recently, the majority of EV-A71 vaccine candidates have been developed for parenteral immunization. However, parenteral vaccine candidates often induce poor mucosal responses. On the other hand, oral vaccines could induce effective mucosal and systemic immunity, and could be easily and safely administered. Thus, proper oral vaccines have attached more interest compared with parenteral vaccine. In this study, the major immunogenic capsid protein of EV-A71 was displayed on the surface of Saccharomyces cerevisiae . Oral immunization of mice with surface-displayed VP1 S. cerevisiae induced systemic humoral and mucosal immune responses, including virus-neutralizing titers, VP1-specific antibody, and the induction of Th1 immune responses in the spleen. Furthermore, oral immunization of mother mice with surface-displayed VP1 S. cerevisiae conferred protection to neonatal mice against the lethal EV-A71 infection. Furthermore, we observed that multiple boost immunization as well as higher immunization dosage could induce higher EV-A71-specific immune response. Our results demonstrated that surface-displayed VP1 S. cerevisiae could be used as potential oral vaccine against EV-A71 infection.